Abstract:Hepatic fibrosis is a pathological condition of liver disease with an increasing number of cases worldwide. Therapeutic strategies are warranted to target the activated hepatic stellate cells (HSCs), the collagen‐producing cells, an effective strategy for controlling the disease progression. Benzimidazoisoquinoline derivatives were synthesized as hybrid molecules by the combination of benzimidazoles and isoquinolines to evaluate their anti‐fibrotic potential using an in‐vitro and in‐vivo model of hepatic fibrosis. A small library of benzimidazoisoquinoline derivatives (1‐17 and 18‐21) was synthesized from 2‐aryl benzimidazole and acetylene functionalities through C‐H and N‐H activation. Compounds (10 and its recently synthesized derivatives 18‐21) depicted a significant decrease in PDGF‐BB and/or TGFβ–induced proliferation (1.7‐1.9 ‐fold), migration (3.5‐5.0 ‐fold), and fibrosis‐related gene expressions in HSCs. These compounds could revert the hepatic damage caused by chronic exposure to hepatotoxicants, ethanol, and/or carbon tetrachloride as evident from the histological, biochemical, and molecular analysis. Anti‐fibrotic effect of the compounds was supported by the decrease in the malondialdehyde level, collagen deposition, and gene expression levels of fibrosis‐related markers such as α‐SMA, COL1α1, PDGFRβ, and TGFRIIβ in the preclinical models of hepatic fibrosis. In conclusion, the synthesized benzimidazoisoquinoline derivatives (compounds 18, 19, 20, and 21) possess anti‐fibrotic therapeutic potential against liver fibrosis.

Synthesis and Biological Evaluation of Fluorinated 3,4-Dihydroquinolin-2(1h)-ones and 2-Oxindoles for Anti-Hepatic Fibrosis

Synthesis and biological evaluation of fluorinated 3,4- dihydroquinolin-2(1 H )-ones and 2-oxindoles for anti-hepatic fibrosis

Synthesis, Structural Characterization, Hirshfeld Surface, DFT Calculation and Antifungal Activity of Novel Quinoline Carbonothioate Compounds

Synthesis, Crystal Structures, Fluorescence and Xanthine Oxidase Inhibitory Activity of Pyrazole-Based 1,3,4-Oxadiazole Derivatives

Synthesis of Novel 2-(Pyridin-2-yl) Pyrimidine Derivatives and Study of Their Anti-Fibrosis Activity

Synthesis, Molecular Modeling, and Biological Evaluation of Quinazoline Derivatives Containing the 1,3,4-Oxadiazole Scaffold As Novel Inhibitors of VEGFR2

Design, synthesis and anti-hepatic fibrosis activity of novel diphenyl vitamin D receptor agonists

Design, synthesis and biological evaluation studies of novel anti-fibrosis agents bearing sulfoxide moiety

Design, synthesis, biological evaluation and docking study of novel quinazoline derivatives as EGFR-TK inhibitors

Discovery of 1,8-naphthalidine derivatives as potent anti-hepatic fibrosis agents via repressing PI3K/AKT/Smad and JAK2/STAT3 pathways

Design, Synthesis, and Biological Evaluation of Quinazoline Derivatives with Covalent Reversible Warheads As Potential FGFR4 Inhibitors

One-pot synthesis and pharmacological evaluation of new quinoline/pyrimido-diazepines as pulmonary antifibrotic agents

Design, Synthesis, and Biological Evaluation of Novel Evodiamine Derivatives As Potential Antihepatocellular Carcinoma Agents

Synthesis and Biological Evaluation of Novel Fluorinated Anticancer Agents Incorporating the Indolin-2-One Moiety

Synthesis and evaluation of 5-benzylidenethiazolidine-2,4-dione derivatives for the treatment of non-alcoholic fatty liver disease

Therapeutic Potential of Benzimidazoisoquinoline Derivatives in Alleviating Murine Hepatic Fibrosis

Synthesis, Antiproliferative Evaluation, and Structure-Activity Relationships of 3-Arylquinolines

Synthesis and biological evaluation of 3,4-diaryl-5-aminoisoxazole derivatives.

Synthesis, Molecular Modeling and Biological Evaluation of 2-Aminomethyl-5-(quinolin-2-yl)-1,3,4-oxadiazole-2(3h)-thione Quinolone Derivatives As Novel Anticancer Agent

Synthesis and evaluation of a novel series of quinoline derivatives with immunosuppressive activity.

Design, synthesis and biological evaluation of quinazoline derivatives as potent and selective FGFR4 inhibitors